Srinivas Akkaraju, Director at Mineralys Therapeutics, Inc. (MLYS), bought 600,000 shares at $13.50 ($8.1M) on 2025-03-13, disclosed to the SEC on 2025-03-17.
Open-market purchase of $8.1M MLYS by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| KLRS | BUY | 2026-05-22 | $1.2M | — | Filing → |
| ALMS | BUY | 2026-01-13 | $10.0M | — | Filing → |
| SRRK | BUY | 2025-12-16 | $1.9M | — | Filing → |